Zimmer Biomet CEO and leadership

Prior to joining Zimmer Biomet, Mr. Hanson served as a member of Medtronic’s Executive Committee and as Executive Vice President and Group President, Minimally Invasive Therapies Group of Medtronic, where he oversaw and provided strategic direction to that approximately $9 billion business. Prior to joining Medtronic, Mr. Hanson served as Group President, Covidien, with global responsibility for all Covidien business segments. Prior to being elevated to that newly created position, Mr. Hanson served as Group President, Medical Devices & U.S. of Covidien and prior to that, he served as Group President, Surgical Solutions and President, Energy-based Devices. Mr. Hanson began his career with Covidien in 1992. He holds a Bachelor of Science degree in Finance from Florida State University. He also completed the Kellogg School of Management Finance for Executives program in 2010 and the Harvard Executive Education in Leadership program in 2013. Mr. Hanson serves on the board of the Advanced Medical Technology Association (AdvaMed), the medical device industry’s association and is a member of the International Board Committee. He also serves on the board of AmeriCares, an emergency response and global health organization committed to saving lives and building healthier futures for people in crisis.

Rachel Ellingson was appointed Senior Vice President and Chief Strategy Officer in April 2018.

Prior to joining the Company, Ms. Ellingson served as Vice President, Corporate Strategy and as a member of the executive leadership team at St. Jude Medical. Before joining St. Jude Medical, she served as Vice President, Business Development and Investor Relations at AGA Medical Corporation. Previously, she served in a number of leadership roles in investment banking firms, including Bank of America and Cowen & Company. Ms. Ellingson holds a Bachelor of Arts degree from the University of Rhode Island and an MBA in Finance from the University of Connecticut.

Dynamic, outcomes driven Human Resources Leader with demonstrated track record for impacting business results through strategy development and execution, deep experience in talent management, organizational effectiveness, capability assessment and change leadership, Proven track record for developing innovative, solution driven strategies in service of business needs and creating value by developing capabilities, programs and processes that advance organizational strategy. Strong leadership coaching orientation and extensive client support in both fully integrated, commercial business models and critical global functions including Finance, Research & Development, Sales and Marketing, Product Development, Strategic Regulatory Affairs, Clinical Research and Operations, Healthcare Compliance, Program Management, Franchise Development and Medical Affairs, Health Outcomes. Strong social intelligence with an ability to work effectively with C-suite executives and senior leadership teams.

Specialties: Developing key talent strategies linked to critical business needs; moving ideas to actionable results; coaching leaders at all organizational levels, extensive work in M&A integrations with emphasis on talent; deep experience in driving change by translating concepts into tangible actions and through strong collaboration and relationship building skills.

Suketu 'Suky' Upadhyay is a Board Member at Auxilium Pharmaceuticals; EVP & CFO at ZIMMER BIOMET HOLDINGS, INC.; and Board Member at Litha Healthcare Group Ltd and is based in Stamford, Connecticut. He has worked as Global Head of R&D Finance at Astra Zeneca, Exec VP/CFO at ENDO INTERNATIONAL, and Executive Finance Director - Centocor at Johnson & Johnson. Suketu works or has worked at KPMG. He attended Ursinus College between 1992 and 1993, Fuqua School of Business between 2003 and 2005, and Albright College between 1987 and 1991.

Angela Main was appointed Senior Vice President, Global Chief Compliance Officer and Associate General Counsel, Asia Pacific in June 2015. She is responsible for the provision of compliance advice and ethical solutions to the Zimmer Biomet organization, including developing, operating and monitoring the Company’s Compliance Program.

Ms. Main served as Vice President, Legal and Compliance, Asia Pacific for Zimmer Biomet from September 2010 to June 2015. Prior to joining the Company in 2010, she worked for Covidien in Singapore, Lloyds TSB Bank plc in London and Texas Instruments in its European and Asia Pacific regional offices. She has extensive international legal and compliance experience in the healthcare, financial services and technology sectors.

Ellie Humphrey was appointed Senior Vice President and Chief Transformation Officer in January 2021. She is responsible for connecting key initiatives and implementing a higher level, more integrated transformation strategy across the organization.

Prior to joining Zimmer Biomet, Ms. Humphrey served as Vice President, Enterprise Excellence and Business Transformation at Medtronic. During her 11-year tenure with the company, she held several leadership roles with a focus on defining the company’s global growth strategy, including portfolio, resource and investment allocation, and performance management. Previously, Ms. Humphrey spent eight years at McKinsey & Company advising corporate clients with a focus on growth, commercial, operational and business development strategies. She holds a JD from the University of Virginia School of Law, MBA from the Darden School of Business, and an AB, cum laude, from Harvard College.

Prior to joining Zimmer Biomet, Mr. Hanson served as a member of Medtronic’s Executive Committee and as Executive Vice President and Group President, Minimally Invasive Therapies Group of Medtronic, where he oversaw and provided strategic direction to that approximately $9 billion business. Prior to joining Medtronic, Mr. Hanson served as Group President, Covidien, with global responsibility for all Covidien business segments. Prior to being elevated to that newly created position, Mr. Hanson served as Group President, Medical Devices & U.S. of Covidien and prior to that, he served as Group President, Surgical Solutions and President, Energy-based Devices. Mr. Hanson began his career with Covidien in 1992. He holds a Bachelor of Science degree in Finance from Florida State University. He also completed the Kellogg School of Management Finance for Executives program in 2010 and the Harvard Executive Education in Leadership program in 2013. Mr. Hanson serves on the board of the Advanced Medical Technology Association (AdvaMed), the medical device industry’s association and is a member of the International Board Committee. He also serves on the board of AmeriCares, an emergency response and global health organization committed to saving lives and building healthier futures for people in crisis.